Market closed
Aura Biosciences/$AURA
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Aura Biosciences
Aura Biosciences Inc is a clinical-stage biotechnology company developing precision immunotherapies to treat a range of solid tumors designed to preserve the function of organs afflicted with cancer. Its lead candidate bel-sar is in late-stage clinical development for the treatment of patients with primary choroidal melanoma, and other ocular oncology indications as well as in early-stage clinical development in bladder cancer. The Company views its operations and manages its business in one operating segment operating exclusively in the United States.
Ticker
$AURA
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
89
Website
Aura Biosciences Metrics
BasicAdvanced
$375M
-
-$1.72
0.33
-
Price and volume
Market cap
$375M
Beta
0.33
52-week high
$11.39
52-week low
$6.63
Average daily volume
167K
Financial strength
Current ratio
12.47
Quick ratio
11.851
Long term debt to equity
9.136
Total debt to equity
10.926
Management effectiveness
Return on assets (TTM)
-30.22%
Return on equity (TTM)
-50.99%
Valuation
Price to book
2.14
Price to tangible book (TTM)
2.14
Price to free cash flow (TTM)
-4.865
Growth
Earnings per share change (TTM)
-11.37%
3-year earnings per share growth (CAGR)
-73.92%
What the Analysts think about Aura Biosciences
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for Aura Biosciences stock.
Aura Biosciences Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
Aura Biosciences Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Aura Biosciences News
AllArticlesVideos
Aura Biosciences Announces Additional Data from Ongoing Phase 1 Trial in Non-Muscle Invasive Bladder Cancer to be Presented as a Late-Breaking Abstract at the 40th Annual European Association of Urology Congress
GlobeNewsWire·3 weeks ago
Aura Biosciences to Participate in Upcoming Investor Conferences
GlobeNewsWire·4 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Aura Biosciences stock?
Aura Biosciences (AURA) has a market cap of $375M as of March 23, 2025.
What is the P/E ratio for Aura Biosciences stock?
The price to earnings (P/E) ratio for Aura Biosciences (AURA) stock is 0 as of March 23, 2025.
Does Aura Biosciences stock pay dividends?
No, Aura Biosciences (AURA) stock does not pay dividends to its shareholders as of March 23, 2025.
When is the next Aura Biosciences dividend payment date?
Aura Biosciences (AURA) stock does not pay dividends to its shareholders.
What is the beta indicator for Aura Biosciences?
Aura Biosciences (AURA) has a beta rating of 0.33. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.